TOKYO–(BUSINESS WIRE)–R-Tech Ueno (JASDAQ:4573) This is to announce that R-Tech Ueno, Ltd. (Head Office: Chiyoda-ku, Tokyo, CEO and President: Yukihiko Mashima, hereinafter referred to as “R-Tech Ueno”) has acquired the right to develop and commercia…
Category: Business
II-VI Optical Systems to Debut Most Recent Capabilities Integration at the 2015 SPIE-DSS Show
MURRIETA, Calif.–(BUSINESS WIRE)–II-VI Optical Systems (II-VI OS) will present at the SPIE-DSS show in Baltimore Maryland, April 20-23, 2015, Booth #725.
Technavio Publishes Market Forecast and Analysis on the Smart Glasses Market for Augmented Reality 2015-2019
LONDON–(BUSINESS WIRE)–Technavio has published a new report on the smart glasses market for augmented reality (AR), which is expected to grow at a CAGR 194.2% from 2015-2019.
Icon Bioscience Announces Pivotal Phase 3 Clinical Data Demonstrates Exceptional Efficacy of IBI-10090 in Reducing Inflammation Associated with Cataract Surgery
SUNNYVALE, Calif.–(BUSINESS WIRE)–Phase 3 trial data showed that IBI-10090 is highly effective in treating inflammation post cataract surgery.
Clarity Medical’s RetCam Will Be Used in a Worldwide Clinical Study for the Treatment of Premature Infant Ocular Disease
PLEASANTON, Calif.–(BUSINESS WIRE)–Clarity Medical Systems, Inc., a developer and marketer of ophthalmic diagnostic imaging technologies, is pleased to announce that their product, RetCam, will be utilized to image premature infant eyes in a study to evaluate a potential new method for treating Retinopathy of Prematurity (ROP) using Lucentis™ (ranibizumab). “The use of RetCam in a study of this medical significance demonstrates the growing worldwide acceptance of RetCam for pediatric retinal
pSivida VP of Research to Discuss Company’s Protein and Antibody Sustained Delivery System at 5th Ocular Diseases and Drug Development Conference
WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida VP of Research to discuss company’s protein and antibody sustained delivery system at upcoming Ocular diseases and drug conference
Customer Survey Shows High Satisfaction Rate with ReVision Optics’ Near Vision Inlay for Presbyopia
LAKE FOREST, Calif.–(BUSINESS WIRE)–ReVision Optics®, Inc. (RVO), a leader in implantable inlay technology to treat presbyopia, reported a high level of satisfaction from a group of 58 patients treated for presbyopia at the Ultralase Clinics in the …
Sprint Launches Code Factory Mobile Accessibility Application for Free to Android Users Who Are Blind or Have Low Vision
SAN DIEGO–(BUSINESS WIRE)–Free app is now available, making Android smartphones more accessible for postpaid and no-contract Sprint customers
OptiMedica Begins U.S. Shipments of the Catalys™ Precision Laser System; First U.S. Patients Treated at Mann Eye Institute, Houston
SANTA CLARA, Calif.–(BUSINESS WIRE)–OptiMedica begins shipping the Catalys Precision Laser System for cataract surgery in the U.S. First U.S. patients have been treated at Mann Eye Institute in Houston.
Status of Strategic Partnership Discussions Related to RGN-259 Ophthalmic Eye Drop
ROCKVILLE, Md.–(BUSINESS WIRE)–RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) is updating stockholders on the status of strategic discussions related to its ophthalmic drug candidate, RGN-259. Since…
pSivida Corp. to Hold Monday November 14 Conference Call to Discuss Complete Response Letter for ILUVIEN® for DME and pSivida’s Product Pipeline
WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida to hold conference call Monday to discuss product pipeline and CRL from FDA for ILUVIEN
OPKO Announces Sale of Ophthalmic Instrumentation Business
MIAMI–(BUSINESS WIRE)–OPKO Health, Inc. (NYSE: OPK) has agreed to sell its ophthalmic instrumentation business to OPTOS, Inc., a subsidiary of Optos plc, a leading and rapidly growing medical technology company engaged in the design, development, man…
AGTC Receives Grant from the Foundation Fighting Blindness for Pre-Clinical Study of Gene Therapy for Eye Disease
GAINESVILLE, Fla.–(BUSINESS WIRE)–AGTC receives significant grant funding from the Foundation Fighting Blindness to develop treatment for genetic eye disease, XLRS, causing blindness in young boys.
Acucela and Otsuka Pharmaceutical Announce the Initiation of a Phase 1/2 Clinical Trial for OPA-6566 in Patients with Open-angle Glaucoma or Ocular Hypertension
SEATTLE & TOKYO–(BUSINESS WIRE)–Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, and Otsuka Pharmaceutical Co., Ltd., today announced the initiation of a Phase 1/2 clinical trial for…
SARcode Bioscience Completes $44 Million Series B Financing
SARcode Bioscience, Inc., a privately-held biopharmaceutical company, announced today the completion of a $44 million Series B private equity financing. The financing round was led by Sofinnova Ventures and was augmented by the additional backing of Rh…
PowerVision Adds Medtronic as a Strategic Investor
PowerVision, Inc., a private company developing an accommodating intraocular lens, announced that it had added Medtronic to its list of investors in a recent closing of its Series C financing. Stephen Oesterle, MD, Senior Vice President, Medicine and T…
Transcend Medical Closes $51M Series B Financing
Transcend Medical, Inc., an ophthalmic device company dedicated to developing minimally invasive glaucoma therapies, announced the closure of its second tranche, bringing the total of Series B to $51M. Investor Growth Capital (IGC) joined this tranche,…
LensAR Focuses On $2M of $7M Offering for Laser 3D Imaging Tech
Orlando-based LensAR has raised $2 million of a targeted $7 million offering, according to a regulatory filing. The company is developing and commercializing laser and 3D imaging technology for refractive cataract surgery. The company raised $7 million in equity in…
EyeMed Vision Care Expands Member Wellness Focus with Diabetic Eye Care Benefit
MASON, Ohio–(BUSINESS WIRE)–EyeMed Vision Care introduces a new Diabetic Eye Care benefit that provides follow-up care and supplementary diagnostic testing for patients with diabetes, a leading cause of adult blindness.
Neurotech’s NT-501 Implant Slows Vision Loss in Patients with Geographic Atrophy Associated with Dry AMD as Reported in PNAS
LINCOLN, R.I.–(BUSINESS WIRE)–Neurotech announced that it was reported in PNAS that its product candidate NT-501 slowed progression of vision loss in patients with geographic atrophy associated with dry AMD in a Phase 2 study.